The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 20, 2011
Filed:
Jan. 15, 2009
Jackie Papkoff, San Francisco, CA (US);
Glenn Pilkington, Rye, AU;
Gilbert-andre Keller, Belmont, CA (US);
Wenlu LI, South San Francisco, CA (US);
Laura Corral, Belmont, MA (US);
Iris Simon, Amsterdam, NL;
Muriel Kmet, Palo Alto, CA (US);
Jianwen Tang, Freemont, CA (US);
Jackie Papkoff, San Francisco, CA (US);
Glenn Pilkington, Rye, AU;
Gilbert-Andre Keller, Belmont, CA (US);
Wenlu Li, South San Francisco, CA (US);
Laura Corral, Belmont, MA (US);
Iris Simon, Amsterdam, NL;
Muriel Kmet, Palo Alto, CA (US);
Jianwen Tang, Freemont, CA (US);
diaDexus, Inc., South San Francisco, CA (US);
Abstract
The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Pro104) antibodies that bind to Pro104 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro104 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro104 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro104 antibodies. The invention encompasses a method of producing the anti-Pro104 antibodies. Other aspects of the invention are a method of killing a Pro104-expressing cancer cell, comprising contacting the cancer cell with an anti-Pro104 antibody and a method of alleviating or treating a Pro104-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Pro104 antibody to the mammal.